Abstracts tagged "Big data"

Abstract Number: 1234 • 2017 ACR/ARHP Annual Meeting
How Machine Learning Statistics Can Change the Game of Data Analysis in Rheumatology: The Example a Study with 170 Patients with Rheumatoid Arthritis (ra) or Axial Spondyloarthritis (axspa)
Frédéric Guyard¹, Laure Gossec², Didier Leroy³, Thomas Lafargue¹, Michel Seiler³, Charlotte Jacquemin⁴, Anna Molto⁵, Jeremie Sellam⁶, Violaine Foltz⁴, Frédérique Gandjbakhch⁴, Christophe Hudry⁷, Stéphane Mitrovic⁴, Bruno Fautrel⁴ and Herve Servy⁸, ¹IMT, Orange, Nice, France, ²UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ³Healthcare, Orange, Paris, France, ⁴UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Rheumatology, Saint-Antoine Hospital, Paris, France, ⁷AP-HP Hôpital Cochin, Paris, France, ⁸e-health services, Sanoia, Gemenos, France
Background/Purpose: A link between flares and physical activity would confirm the objective consequences of flares. In the ActConnect study of patients with RA or axSpA,…
Abstract Number: 2609 • 2017 ACR/ARHP Annual Meeting
A Systematic Literature Mining and Gene Expression Analysis Identifies Possible Drug Candidates for Repositioning in Lupus
Peter E. Lipsky, Matt Ryals, Adam Labonte, Sarah Heuer, James Dittman, Michelle Catalina and Amrie Grammer, AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: Since new therapies for lupus have been extremely slow to develop and lupus patients have a great unmet medical need, an independent pharma-external effort…
Abstract Number: 807 • 2016 ACR/ARHP Annual Meeting
A Novel Multi-Network Approach Reveals Tissue-Specific Cellular Modulators of Fibrosis in Systemic Sclerosis, Pulmonary Fibrosis and Pulmonary Arterial Hypertension
Jaclyn N. Taroni¹, Casey S. Greene², Tammara A. Wood³, Romy B. Christmann⁴, Harrison W. Farber⁵, Robert A. Lafyatis⁶, Christopher Denton⁷, Monique Hinchcliff⁸, Patricia A. Pioli⁹, Michael L. Whitfield¹⁰ and J. Matthew Mahoney¹¹, ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Division of Rheumatology, Boston University Medical School, Boston, MA, ⁵Pulmonary Center, Boston University Medical Center, Boston, MA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁸Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁹Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, ¹⁰Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ¹¹Department of Neurological Sciences, College of Medicine, University of Vermont, Burlington, VT
Background/Purpose: Systemic sclerosis (SSc) is characterized by multi-organ involvement and clinical heterogeneity. “Big data” approaches have yielded powerful tools to infer tissue-specific pathobiology. Large amounts of…
Abstract Number: 672 • 2016 ACR/ARHP Annual Meeting
Sjogren Big Data Project: Influence of Geolocation on the Phenotypic Expression at Diagnosis in 8310 Patients (North-to-South Gradient)
Pilar Brito-Zerón^1,2, Soledad Retamozo³, Margit Zeher⁴, Astrid Rasmussen⁵, Raphaele Seror⁶, Elke Theander⁷, Xiaomei Li⁸, Chiara Baldini⁹, Jacques-Eric Gottenberg¹⁰, Debashish Danda¹¹, Luca Quartuccio¹², Roberta Priori^13,14, Gabriela Hernandez-Molina¹⁵, Aike A. Kruize¹⁶, Valeria Valim¹⁷, Marika Kvarnström¹⁸, Damien Sene¹⁹, Roberto Gerli²⁰, Sonja Praprotnik²¹, David A. Isenberg²², Roser Solans²³, Maureen Rischmueller²⁴, Seung-Ki Kwok²⁵, Gunnel Nordmark²⁶, Yasunori Suzuki²⁷, Roberto Giacomelli²⁸, Valerie Devauchelle²⁹, Michele Bombardieri³⁰, Benedikt Hofauer³¹, Hendrika Bootsma³², Johan G. Brun³³, Guadalupe Fraile³⁴, Steven E. Carsons³⁵, Tamer Gheita³⁶, Jacques Morel³⁷, Cristina F. Vollenweider³⁸, Fabiola Atzeni³⁹, Nihan Acar-Denizli⁴⁰, Ildike-Fanny Horvath⁴, Kathy Sivils⁵, Thomas Mandl⁴¹, Pulukool Sandhya¹¹, Salvatore De Vita⁴², Jorge Sánchez-Guerrero⁴³, Eefje van der Heijden¹⁶, Virginia Moça Trevisano⁴⁴, Marie Wahren-Herlenius¹⁸, Xavier Mariette⁶, Manuel Ramos-Casals^1,45,46 and EULAR-SS Task Force Big Data Consortium (ASSES, GEAS-SEMI, EULAR), ¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, ³Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ⁴Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁶Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, ⁷Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, ⁸Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ⁹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, ¹¹Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹²Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ¹³Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ¹⁴Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁶Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁷Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ¹⁸Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ¹⁹Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, ²⁰Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, ²¹Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ²²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ²³Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁴Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, ²⁵Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea, ²⁶Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²⁷Division of Rheumatology, Kanazawa University Graduate School of Medicine, Ishikawa, Japan, Kanazawa, Japan, ²⁸Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, ²⁹Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³⁰Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, ³¹Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, ³²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ³³Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ³⁴Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ³⁵Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, ³⁶Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, ³⁷Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, ³⁸Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, ³⁹IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, ⁴⁰Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Turkey, Istabul, Turkey, ⁴¹Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ⁴²Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ⁴³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁴⁴Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, ⁴⁵Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, ⁴⁶Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: To analyse the influence of geolocation (North-to-South gradient) on the clinical presentation of primary Sjögren syndrome (SjS) at diagnosis. Methods: The Big Data Sjögren…
Abstract Number: 1217 • 2015 ACR/ARHP Annual Meeting
Phenome-Wide Association Study of Novel Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jeffrey A. Sparks¹, Boris Hejblum², I-Hsin Kuo¹, Jing Cui¹, Lauren J. Lahey³, Andrew Cagan⁴, Vivian Gainer⁴, Weidong Liu⁵, Tony Cai⁶, Jeremy Sokolove⁷ and Tianxi Cai², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Biostatistics, Harvard School of Public Health, Boston, MA, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Research Computing, Partners HealthCare, Charlestown, MA, ⁵Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China, ⁶Statistics, University of Pennsylvania, Philadelphia, PA, ⁷Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: RA patients develop autoantibodies against a spectrum of antigens. However, the clinical significance of these autoantibodies after RA diagnosis is unclear. The Phenome-Wide Association…
Abstract Number: 2316 • 2014 ACR/ARHP Annual Meeting
Adherence to Denosumab in a Large Healthcare System
Robert A. Overman¹, Julie C. Lauffenburger², Margaret L. Gourlay³ and Chad L. Deal⁴, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ³Family Medicine, University of North Carolina, Chapel Hill, NC, ⁴Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Oral bisphosphonates adherence has been reported as less than 50% at one year. Adherence to denosumab has been reported to be higher than alendronate…
Abstract Number: 2263 • 2014 ACR/ARHP Annual Meeting
Continued Zoledronic Acid Use in a Large Healthcare System
Robert A. Overman¹, Julie C. Lauffenburger², Margaret L. Gourlay³ and Chad L. Deal⁴, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ³Family Medicine, University of North Carolina, Chapel Hill, NC, ⁴Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Oral bisphosphonates adherence has been reported as less than 50% at one year. With patients frequently having refill gaps greater than 30 days. Zoledronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].